Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Stoke Therapeutics Inc shares valued at $185,523 were purchased by JONATHAN ALLAN on Aug 13 ’25. At $13.53 per share, JONATHAN ALLAN acquired 13,712 shares.
Also, Ticho Barry sold 4,504 shares, netting a total of over 57,724 in proceeds. Following the sale of shares at $12.82 each, the insider now holds 16,775 shares.
Before that, Ticho Barry had sold 4,503 shares from its account. In a trade valued at $52,379, the CHIEF MEDICAL OFFICER traded Stoke Therapeutics Inc shares for $11.63 each. Upon closing the transaction, the insider’s holdings decreased to 4,503 shares, worth approximately $0.37 million.
As published in their initiating research note from Jefferies on July 18, 2025, Stoke Therapeutics Inc [STOK] has been a Buy and the price target has been revised to $30. Analysts at Chardan Capital Markets started covering the stock with ‘”a Buy”‘ outlook in a report released in mid December. Earlier on March 26, 2024, TD Cowen upgraded its rating. Their new recommendation was “an Outperform” for STOK stock which previously was a “a Market perform”.
Analyzing STOK Stock Performance
On last trading session, Stoke Therapeutics Inc [NASDAQ: STOK] rose 1.54% to $17.17. The stock’s lowest price that day was $15.5036, but it reached a high of $17.32 in the same session. During the last five days, there has been a surge of approximately 29.58%. Over the course of the year, Stoke Therapeutics Inc shares have jumped approximately 18.86%. Shares of the company reached a 52-week high of $17.61 on 08/13/25 and a 52-week low of $5.35 on 04/09/25.
Support And Resistance Levels for Stoke Therapeutics Inc (STOK)
According to the 24-hour chart, there is a support level at 16.01, which, if violated, would cause prices to drop to 14.84. In the upper region, resistance lies at 17.83. The next price resistance is at 18.48. RSI (Relative Strength Index) is 80.59 on the 14-day chart, showing overbought technical sentiment.
Is Stoke Therapeutics Inc subject to short interest?
Stocks of Stoke Therapeutics Inc saw a sharp steep in short interest on 2025-07-31 dropping by -0.1 million shares to 11.43 million. Data from Yahoo Finance shows that the short interest on 2025-06-30 was 11.53 million shares. A decline of -0.91% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 15.4 of the overall float, the days-to-cover ratio (short ratio) decline to 15.4.
Which companies own the most shares of Stoke Therapeutics Inc (STOK)?
In terms of Stoke Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 22 in the next 12 months, up nearly 30.1% from the previous closing price of $16.91. Analysts anticipate Stoke Therapeutics Inc stock to reach 58 by 2025, with the lowest price target being 18. In spite of this, 5 analysts ranked Stoke Therapeutics Inc stock as Buy at the end of 2025.
